Along with activation of the Akt pathway, estrogen promoted EMT and proliferation in Brca1-deficient mammary tumor cells, which prompted us to test whether pharmaceutical inhibition of Akt activity has any effect on Brca1-deficient cell proliferation and tumor progression. This evidence concerns the gene BRCA1 and breast cancer.